Brett D. Anderson

Brett D. Anderson

Auto-generated profile, based on publicly available information

Brett D. Anderson

Miromatrix Medical Inc, Eden Prairie, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2011 in Nature
Verified
Journal Article
Closed access
PDF file
SJStefanie Jäger
Stefanie Jäger
DKDong Young Kim
Dong Young Kim
JHJudd F. Hultquist
Judd F. Hultquist
KSKeisuke Shindo
Keisuke Shindo
RLRebecca S. LaRue
Rebecca S. LaRue
NKNevan J. Krogan
Nevan J. Krogan

1 June 2013 in Structure
Verified
Journal Article
Closed access
MBMarkus-Frederik Bohn
Markus-Frederik Bohn
SSShivender M.D. Shandilya
Shivender M.D. Shandilya
JAJohn S. Albin
John S. Albin
TKTakahide Kouno
Takahide Kouno
BABrett D. Anderson
Brett D. Anderson
CSCelia Schiffer
Celia Schiffer

14 October 2019 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
MSMohammed F. Shaheen
Mohammed F. Shaheen
DJDong Jin Joo
Dong Jin Joo
JRJeffrey J. Ross
Jeffrey J. Ross
BABrett D. Anderson
Brett D. Anderson
HCHarvey S. Chen
Harvey S. Chen
Scott NybergScott Nyberg
Scott Nyberg

15 September 2016 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
BLBrandon Leonard
Brandon Leonard
GSGabriel J. Starrett
Gabriel J. Starrett
MMMatthew J. Maurer
Matthew J. Maurer
AOAnn L. Oberg
Ann L. Oberg
MBMieke Rosalie Van Bockstal
Mieke Rosalie Van Bockstal
RHReuben Harris
Reuben Harris
Purpose: APOBEC3 DNA cytosine deaminase family members normally defend against viruses and transposons. However, deregulated APOBEC3 activity causes mutations in cancer. Because of broad expression profiles and varying mixtures of normal and cancer cells in tumors, including immune cell infiltration, it is difficult to determine where different APOBEC3s are expressed. Here, we ask whether correlations exist between APOBEC3 expression and T-cell infiltration in high-grade serous ovarian cancer (HGSOC), and assess whether these correlations have prognostic value. Experimental Design: Transcripts for APOBEC3G, APOBEC3B, and the T-cell markers, CD3D, CD4, CD8A, GZMB, PRF1, and RNF128 were quantified by RT-qPCR for a cohort of 354 HGSOC patients. Expression values were correlated with each other and clinical parameters. Two additional cohorts were used to extend HGSOC clinical results. Immunoimaging was used to colocalize APOBEC3G and the T-cell marker CD3. TCGA data extended expression analyses to additional cancer types. Results: A surprising positive correlation was found for expression of APOBEC3G and several T cell genes in HGSOC. Immunohistochemistry and immunofluorescent imaging showed protein colocalization in tumor-infiltrating T lymphocytes. High APOBEC3G expression correlated with improved outcomes in multiple HGSOC cohorts. TCGA data analyses revealed that expression of APOBEC3D and APOBEC3H also correlates with CD3D across multiple cancer types. Conclusions: Our results identify APOBEC3G as a new candidate biomarker for tumor-infiltrating T lymphocytes and favorable prognoses for HGSOC. Our data also highlight the complexity of the tumor environment with respect to differential APOBEC family gene expression in both tumor and surrounding normal cell types. Clin Cancer Res; 22(18); 4746–55. ©2016 AACR.

4 September 2015 in Science Advances
Verified
Journal Article
Open access
PDF file
BABrett D. Anderson
Brett D. Anderson
RHReuben Harris
Reuben Harris
A diverse set of innate immune mechanisms protects cells from viral infections. The APOBEC3 family of DNA cytosine deaminases is an integral part of these defenses. For instance, APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H would have the potential to destroy HIV-1 complementary DNA replication intermediates if not for neutralization by a proteasomal degradation mechanism directed by the viral protein Vif. At the core of this complex, Vif heterodimerizes with the transcription cofactor CBF-β, which results in fewer transcription complexes between CBF-β and its normal RUNX partners. Recent studies have shown that the Vif/CBF-β interaction is specific to the primate lentiviruses HIV-1 and SIV (simian immunodeficiency virus), although related nonprimate lentiviruses still require a Vif-dependent mechanism for protection from host species’ APOBEC3 enzymes. We provide a molecular explanation for this evolutionary conundrum by showing that CBF-β is required for expression of the aforementioned HIV-1–restrictive APOBEC3 gene repertoire. Knockdown and knockout studies demonstrate that CBF-β is required for APOBEC3 mRNA expression in the nonpermissive T cell line H9 and in primary CD4+ T lymphocytes. Complementation experiments using CBF-β separation-of-function alleles show that the interaction with RUNX transcription factors is required for APOBEC3 transcriptional regulation. Accordingly, the infectivity of Vif-deficient HIV-1 increases in cells lacking CBF-β, demonstrating the importance of CBF-β/RUNX–mediated transcription in establishing the APOBEC3 antiviral state. These findings demonstrate a major layer of APOBEC3 gene regulation in lymphocytes and suggest that primate lentiviruses evolved to hijack CBF-β in order to simultaneously suppress this potent antiviral defense system at both transcriptional and posttranslational levels.

10 September 2019 in Antibodies
Verified
Journal Article
Open access
PDF file
WBWilliam L. Brown
William L. Brown
ELEmily K. Law
Emily K. Law
PAProkopios P. Argyris
Prokopios P. Argyris
MCMichael A. Carpenter
Michael A. Carpenter
RLRena Levin-Klein
Rena Levin-Klein
RHReuben Harris
Reuben Harris
The DNA cytosine deaminase APOBEC3B (A3B) is normally an antiviral factor in the innate immune response. However, A3B has been implicated in cancer mutagenesis, particularly in solid tumors of the bladder, breast, cervix, head/neck, and lung. Here, we report data on the generation and characterization of a rabbit monoclonal antibody (mAb) for human A3B. One mAb, 5210-87-13, demonstrates utility in multiple applications, including ELISA, immunoblot, immunofluorescence microscopy, and immunohistochemistry. In head-to-head tests with commercial reagents, 5210-87-13 was the only rabbit monoclonal suitable for detecting native A3B and for immunohistochemical quantification of A3B in tumor tissues. This novel mAb has the potential to enable a wide range of fundamental and clinical studies on A3B in human biology and disease.